Iraq to India Pharmaceutical Import

The pharmaceutical trade corridor between Iraq and India has experienced gradual development over the past few years. Between 2022 and 2026, India imported a total of $215,000 worth of pharmaceutical formulations from Iraq, distributed across 14 shipments. This indicates a steady, albeit modest, growth in bilateral pharmaceutical trade. The average shipment value stands at approximately $15,000, reflecting a consistent demand for specific pharmaceutical products. The trade involves three foreign suppliers from Iraq and three Indian buyers, suggesting a balanced and collaborative trading environment.

Iraq's contribution to India's pharmaceutical imports remains relatively small. The total import value of $215,000 over four years accounts for a minor fraction of India's overall pharmaceutical imports. The primary categories imported from Iraq include antibiotics, corticosteroids, and antiviral medications, indicating a focus on essential therapeutic areas. This limited volume suggests that while Iraq plays a role in supplying certain pharmaceutical products to India, it is not a major contributor in the broader context of India's pharmaceutical import landscape.

Between 2024 and 2026, there have been no significant policy changes or trade agreements between India and Iraq specifically affecting pharmaceutical imports. The Central Drugs Standard Control Organisation (CDSCO) has maintained its existing regulatory framework for the importation of pharmaceutical products, ensuring consistent standards and procedures. There have been no notable developments in regulatory harmonization between the two countries during this period.

Iraqi pharmaceutical companies seeking to export products to India must navigate the CDSCO registration process. This involves appointing an Authorized Indian Representative (AIR) to act as an intermediary between the foreign manufacturer and Indian authorities. The AIR is responsible for submitting the Integrated Registration Form (IRF) through the CDSCO's SUGAM portal, which requires detailed information about the manufacturer, product, and manufacturing processes. Key documents include a Site Master File, Plant Master File, and a Free Sale Certificate from the country of origin. The registration process is comprehensive, ensuring that imported pharmaceutical products meet India's safety, efficacy, and quality standards.

India requires that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards as outlined by the World Health Organization (WHO). Iraqi manufacturers must obtain a GMP certificate from the National Drug Regulatory Authority, demonstrating compliance with these international standards. The CDSCO may conduct inspections to verify adherence to GMP guidelines, ensuring that imported pharmaceutical products are manufactured under conditions that guarantee their quality and safety.

To import pharmaceutical products into India, Iraqi companies must provide several key documents:

• Import License (Form 10): Issued by the CDSCO, this license authorizes the importation of specific pharmaceutical products.

• Registration Certificate: Confirms that the pharmaceutical product has been registered with the CDSCO, ensuring it meets Indian regulatory standards.

• No Objection Certificate (NOC): Obtained from the National Drug Regulatory Authority, this certificate indicates that the product is approved for sale in the country of origin.

• Test License: Allows for the importation of pharmaceutical products for testing purposes, ensuring they meet the required quality standards.

These documents facilitate the customs clearance process and ensure that imported pharmaceutical products comply with Indian regulations.

The pharmaceutical products imported from Iraq to India primarily consist of antibiotics, corticosteroids, and antiviral medications. Notably, ceftriaxone, an antibiotic, leads the imports with a value of $50,000, accounting for 23.4% of the total import value. Other significant imports include sodium-based products ($42,000, 19.4%), amoxicillin ($34,000, 15.9%), and dexamethasone ($30,000, 14.2%). These products are essential in treating a range of infections and inflammatory conditions, indicating a demand for such medications in the Indian market.

The imports from Iraq to India do not prominently feature innovator drugs, novel formulations, or advanced therapies. The focus remains on essential pharmaceutical products that are widely used and have established efficacy. This suggests that while Iraq contributes to meeting the demand for standard pharmaceutical products in India, it does not significantly supply cutting-edge or specialized medical treatments.

India's importation of pharmaceutical products from Iraq is driven by several factors:

• Patent Protection: Imported generic drugs from Iraq may offer cost-effective alternatives to patented medications, providing access to essential treatments at lower prices.

• Technology Gaps: Certain pharmaceutical products may not be manufactured domestically in India, necessitating imports to meet healthcare needs.

• Quality Requirements: Imported products from Iraq may adhere to international quality standards, ensuring safety and efficacy.

• Disease Burden: The prevalence of specific diseases in India may drive the demand for particular pharmaceutical products, including those imported from Iraq.

These factors collectively influence India's decision to import pharmaceutical products from Iraq, aiming to meet the healthcare demands of its population.

India's import tariff structure for pharmaceutical formulations includes the following components:

• Most Favored Nation (MFN) Tariff Rates: These rates are applied to imports from countries with which India has trade agreements, ensuring non-discriminatory treatment.

• Basic Customs Duty: A standard duty imposed on imported goods, including pharmaceutical products.

• Integrated Goods and Services Tax (IGST): A tax levied on the import of goods, which is applicable to pharmaceutical imports.

• Health Cess: An additional levy on imported pharmaceutical products, intended to fund health-related initiatives.

These tariffs and taxes collectively impact the pricing and competitiveness of imported pharmaceutical products in the Indian market.

As of March 2026, there are no specific Free Trade Agreements (FTAs) between India and Iraq that offer preferential duty rates for pharmaceutical imports. India's participation in regional trade agreements, such as the Regional Comprehensive Economic Partnership (RCEP), does not currently include Iraq, limiting the scope for preferential trade terms in the pharmaceutical sector.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents by ensuring that only genuine innovations receive patent protection. This policy can impact the availability of generic versions of patented drugs. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines, including imported drugs, to ensure affordability. Compulsory licensing provisions allow the government to grant licenses to produce patented drugs without the consent of the patent holder under specific circumstances, such as public health emergencies.

Pharmaceutical shipments from Iraq to India primarily utilize sea routes, with major ports in Iraq such as Umm Qasr serving as departure points. These shipments typically transit through the Arabian Sea, entering India via ports like Mumbai and Chennai. The transit time for sea shipments ranges from 15 to 30 days, depending on the specific ports and shipping lines used. Air freight options are also available, offering faster delivery times but at higher costs.

In Iraq, the Umm Qasr Port is the primary export hub for pharmaceutical products, equipped with facilities to handle bulk and containerized cargo. In India, major import ports such as Mumbai, Chennai, and Kolkata are equipped to handle pharmaceutical shipments, with dedicated facilities for customs clearance and quality inspections. These ports are well-connected and capable of efficiently processing pharmaceutical imports.

Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance, which includes verification of import documentation and compliance with CDSCO regulations. The CDSCO conducts quality testing to ensure that imported pharmaceutical products meet Indian standards. Cold chain management is critical for temperature-sensitive products, and Indian ports are equipped with refrigerated storage facilities to maintain the required conditions. Good Distribution Practice (GDP) compliance is mandatory, ensuring that pharmaceutical products are stored and transported under conditions that maintain their quality and efficacy.

Despite being a major manufacturer of pharmaceuticals, India imports certain products from Iraq due to factors such as patent protection, technology gaps, and the need to meet specific quality requirements. Imported products may offer cost-effective alternatives to domestically produced drugs, especially in the case of generics. Additionally, the importation of certain pharmaceutical products addresses specific healthcare needs